Details of the Drug
General Information of Drug (ID: DMQ0S4B)
Drug Name |
NSC-66209
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5407-46-5; Methyl fluorone black; 2,6,7-Trihydroxy-9-methylxanthen-3-one; NSC-66209; 2,6,7-Trihydroxy-9-methyl-xanthen-3-one; NSC 5426; UNII-KQC69H1NAG; KQC69H1NAG; 3H-Xanthen-3-one, 2,6,7-trihydroxy-9-methyl-; MLS000736515; MLS000123248; CHEMBL175266; 2,6,7-trihydroxy-9-methyl-3H-xanthen-3-one; NSC5426; NSC66209; 9-Methyl-2,3,7-trihydroxy-6-fluorone Hemisulfate; ST057760; SMR000123893; BAS 00532150; 9-METHYL-2,3,7-TRIHYDROXY-6-FLUORONE; EINECS 226-468-8; NSC 66209; AC1Q69RP; AC1L2IJ2; cid_72721; SCHEMBL2781454; CTK4J9473
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 258.23 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||